0 303

Cited 13 times in

A phase II study of preoperative mFOLFOX6 with short-course radiotherapy in patients with locally advanced rectal cancer and liver-only metastasis

 Kyung Hwan Kim  ;  Sang Joon Shin  ;  Min Soo Cho  ;  Joong Bae Ahn  ;  Minkyu Jung  ;  Tae Il Kim  ;  Young Suk Park  ;  Hoguen Kim  ;  Nam Kyu Kim  ;  Woong Sub Koom 
 RADIOTHERAPY AND ONCOLOGY, Vol.118(2) : 369-374, 2016 
Journal Title
Issue Date
Adenocarcinoma/pathology ; Adenocarcinoma/secondary* ; Adenocarcinoma/surgery ; Adenocarcinoma/therapy ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Chemoradiotherapy, Adjuvant/adverse effects ; Chemoradiotherapy, Adjuvant/methods ; Disease-Free Survival ; Dose Fractionation ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; Humans ; Leucovorin/administration & dosage ; Leucovorin/adverse effects ; Liver Neoplasms/pathology ; Liver Neoplasms/secondary* ; Liver Neoplasms/surgery ; Liver Neoplasms/therapy ; Male ; Middle Aged ; Neoadjuvant Therapy/adverse effects ; Neoadjuvant Therapy/methods ; Neoplasm Grading ; Neoplasm Staging ; Organoplatinum Compounds/administration & dosage ; Organoplatinum Compounds/adverse effects ; Rectal Neoplasms/pathology ; Rectal Neoplasms/surgery ; Rectal Neoplasms/therapy* ; Survival Analysis ; Treatment Outcome
Chemotherapy ; Metastasis ; Rectal cancer ; Short-course radiotherapy
BACKGROUND AND PURPOSE: To evaluate the efficacy and safety of upfront mFOLFOX6 followed by short-course radiotherapy (SCRT) and surgery in patients with locally advanced rectal cancer and liver-only metastases. MATERIALS AND METHODS: This single-arm phase II study involved 32 patients. mFOLFOX6 was administered for four cycles followed by SCRT and another four cycles of mFOLFOX6. Surgery was performed 4-6 weeks after the last chemotherapy cycle. The primary endpoint was complete (R0) resection rate. Secondary endpoints were response rate, progression-free survival (PFS), overall survival (OS), and complication rates. RESULTS: Surgical resection of the rectum and liver was performed in 25 patients (78%) and R0 resection was achieved in 20 patients (63%). Local tumor downstaging was observed in 54% of patients. Median OS and PFS were 38 and 9 months, respectively. One patient discontinued treatment due to toxicity and no treatment-related deaths occurred. Patients who progressed after 4 cycles of mFOLFOX6 were less likely to receive resection. CONCLUSIONS: This regimen was safe and effective in inducing local tumor response and achieving R0 resection in this patient population.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
Yonsei Authors
Koom, Woong Sub(금웅섭) ORCID logo https://orcid.org/0000-0002-9435-7750
Kim, Nam Kyu(김남규) ORCID logo https://orcid.org/0000-0003-0639-5632
Kim, Tae Il(김태일) ORCID logo https://orcid.org/0000-0003-4807-890X
Kim, Ho Keun(김호근)
Shin, Sang Joon(신상준) ORCID logo https://orcid.org/0000-0001-5350-7241
Ahn, Joong Bae(안중배) ORCID logo https://orcid.org/0000-0001-6787-1503
Jung, Min Kyu(정민규) ORCID logo https://orcid.org/0000-0001-8281-3387
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.